Measured using an artificial intelligence-based imaging tool, reduced coronary blood flow predicted future cardiovascular ...
Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Strategies guided by instantaneous wave-free ratio and ...
Please provide your email address to receive an email when new articles are posted on . Implementing a CT angiography-derived fractional flow reserve program improved certain outcomes in patients with ...
Safety of Philips’ iFR in the guidance of percutaneous coronary intervention (PCI) for heart disease demonstrated in late-breaking science at TCT 2023 highlighting patient-level outcomes analysis of ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window As a stricter ...
PARIS — New findings from the controversial ORBITA trial provide a lift for percutaneous coronary intervention (PCI) in stable angina but also mixed results for the predictive power of fractional flow ...
Reduced coronary blood flow, measured with an artificial intelligence-based imaging tool, predicted future cardiovascular ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A Mendelian ...
Reduced coronary blood flow, measured with an artificial intelligence-based imaging tool, predicted future cardiovascular events in patients with suspected stable coronary artery disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback